medicine technologies / insurance / unimportant me-too products / manufacturing process / gross domestic product / active pharmaceutical ingredient / insurance premiums / treatment for HIV / manufacturing / open systems / prevention of HIV / patients using products / end product / biological product / HIV care / diagnostic devices / formulated active pharmaceutical ingredient / health insurance providers / combination product / cross license products / pharmaceutical products / standalone product / /
MedicalCondition
HIV / HIV infections / undiagnosed HIV infection / cancer / Malaria / diseases / AIDS / HIV/AIDS / infections / HIV infection / lethal disease / disease / chronic hepatitis B / /
MedicalTreatment
antiretroviral therapy / AID / /
MusicAlbum
North Dakota / Illinois / /
Organization
World Health Organization / World Trade Organization / Federal Trade Commission / European Parliament / Kaiser Foundation / Global Fund / Prize Fund / Subcommittee on Regulation / Business Opportunities / and Energy / African Union / Agency on The High Cost of High Prices for HIV/AIDS Drugs / European Patent Office / Policy Committee on Intellectual Property / Subcommittee on Primary Health / FDA / World Intellectual Property Organization / National Institute of Health / Prize Fund for HIV/AIDS / Committee on Health / Education / Labor and Pensions / HIV/AIDS Prize Fund / Union for the Public Domain / UN Human Rights Council / HIV/Prize Fund / Centers for Disease Control and Prevention / United States government / United States Senate / Center for the Study for Responsive Law / World Bank / Committee on Small Business / U.S. House of Representatives / TDF / /
Position
Director of Knowledge Ecology International / consultant / advisor / McLees MP / U.S. Co-chair / Chairman / /
The de-linkage of R&D costs and drug prices through the Prize Fund for HIV/AIDS will cost less, expand access, accelerate and improve innovation, and replace an incentive system that is expensive, inefficient and unsusta